Current status and future of neoadjuvant immunotherapy for esophageal cancer
10.3760/cma.j.cn115610-20210420-00193
- VernacularTitle:食管癌新辅助免疫治疗的现状及未来
- Author:
Lijie TAN
1
;
Zhiliang HUANG
Author Information
1. 复旦大学附属中山医院胸外科，上海 200032
- Keywords:
Esophageal neoplasms;
Perioperative period;
Neoadjuvant therapy;
Chemoimmunotherapy;
Immunotherapy;
Immune checkpoint inhibitors
- From:
Chinese Journal of Digestive Surgery
2021;20(6):635-638
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors (ICIs) have become an important treatment strategy for advanced esophageal cancer in the first and second line. Currently, the use of ICIs in neoadjuvant therapy is very limited. However, neoadjuvant immunotherapy may bring better survival benefits for patients with early esophageal cancer or with resectable locally advanced esophageal cancer. The authors review relevant studies to discuss the current status and future of neoadjuvant immunotherapy for esophageal cancer.
